Equities analysts expect Cooper Companies Inc (NYSE:COO) to announce earnings per share (EPS) of $2.57 for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Cooper Companies’ earnings, with the highest EPS estimate coming in at $2.87 and the lowest estimate coming in at $2.42. Cooper Companies posted earnings per share of $2.79 in the same quarter last year, which suggests a negative year over year growth rate of 7.9%. The firm is expected to issue its next earnings report on Thursday, March 14th.
According to Zacks, analysts expect that Cooper Companies will report full-year earnings of $11.94 per share for the current fiscal year, with EPS estimates ranging from $11.51 to $12.72. For the next year, analysts expect that the business will report earnings of $13.39 per share, with EPS estimates ranging from $12.85 to $13.76. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Cooper Companies.
Cooper Companies (NYSE:COO) last announced its quarterly earnings results on Thursday, December 6th. The medical device company reported $2.87 EPS for the quarter, missing the consensus estimate of $2.96 by ($0.09). The firm had revenue of $651.50 million for the quarter, compared to analysts’ expectations of $645.25 million. Cooper Companies had a net margin of 5.52% and a return on equity of 17.86%. The business’s quarterly revenue was up 16.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.65 EPS.
COO traded down $34.02 on Friday, hitting $243.01. The company had a trading volume of 1,253,678 shares, compared to its average volume of 333,174. Cooper Companies has a 12-month low of $216.47 and a 12-month high of $283.18. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.58 and a quick ratio of 1.54. The firm has a market capitalization of $13.61 billion, a PE ratio of 21.13, a price-to-earnings-growth ratio of 2.13 and a beta of 0.77.
In other news, COO Daniel G. Mcbride sold 10,310 shares of the company’s stock in a transaction that occurred on Thursday, September 13th. The stock was sold at an average price of $264.44, for a total transaction of $2,726,376.40. Following the completion of the transaction, the chief operating officer now directly owns 38,705 shares of the company’s stock, valued at approximately $10,235,150.20. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Allan E. Rubenstein sold 1,500 shares of the company’s stock in a transaction that occurred on Thursday, September 13th. The stock was sold at an average price of $265.37, for a total value of $398,055.00. Following the transaction, the director now directly owns 3,068 shares of the company’s stock, valued at $814,155.16. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 20,691 shares of company stock valued at $5,527,869. Corporate insiders own 1.60% of the company’s stock.
Several hedge funds have recently made changes to their positions in COO. Findlay Park Partners LLP raised its stake in shares of Cooper Companies by 225.0% during the 3rd quarter. Findlay Park Partners LLP now owns 738,824 shares of the medical device company’s stock worth $204,765,000 after buying an additional 511,518 shares during the period. Janus Henderson Group PLC raised its stake in shares of Cooper Companies by 23.8% during the 2nd quarter. Janus Henderson Group PLC now owns 2,618,690 shares of the medical device company’s stock worth $616,595,000 after buying an additional 502,783 shares during the period. Putnam Investments LLC raised its stake in shares of Cooper Companies by 228.5% during the 3rd quarter. Putnam Investments LLC now owns 622,865 shares of the medical device company’s stock worth $172,627,000 after buying an additional 433,242 shares during the period. Morgan Stanley raised its stake in shares of Cooper Companies by 734.7% during the 3rd quarter. Morgan Stanley now owns 177,658 shares of the medical device company’s stock worth $49,238,000 after buying an additional 156,373 shares during the period. Finally, Marshall Wace North America L.P. raised its stake in shares of Cooper Companies by 875.3% during the 3rd quarter. Marshall Wace North America L.P. now owns 144,900 shares of the medical device company’s stock worth $40,159,000 after buying an additional 130,043 shares during the period.
About Cooper Companies
The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.
Featured Story: What Is An Exchange-Traded Fund (ETF)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.